DOI . ORG {}

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Doi.org Make Money
Keywords
Topics
Questions
Schema
Social Networks
External Links
Analytics And Tracking
Libraries
Hosting Providers
CDN Services

We began analyzing https://aacrjournals.org/clincancerres/article/11/16/5920/185630/High-Dose-Radioimmunotherapy-Combined-with-Fixed, but it redirected us to https://aacrjournals.org/clincancerres/article/11/16/5920/185630/High-Dose-Radioimmunotherapy-Combined-with-Fixed. The analysis below is for the second page.

Title[redir]:
High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse Antibody | Clinical Cancer Research | American Association for Cancer Research
Description:
Abstract. Purpose: Although radioimmunotherapy alone is effective in lymphoma, its application to solid tumors will likely require a combined modality approach. In these phase I studies, paclitaxel was combined with radioimmunotherapy in patients with metastatic hormone-refractory prostate cancer or advanced breast cancer.Experimental Design: Patients were imaged with indium-111 (111In)-1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid-peptide-m170. One week later, yttrium-90 (90Y)-m170 was infused (12 mCi/m2 for prostate cancer and 22 mCi/m2 for breast cancer). Initial cohorts received radioimmunotherapy alone. Subsequent cohorts received radioimmunotherapy followed 48 hours later by paclitaxel (75 mg/m2). Cyclosporine was given to prevent development of human anti-mouse antibody.Results: Bone and soft tissue metastases were targeted by 111In-m170 in 15 of the 16 patients imaged. Three prostate cancer patients treated with radioimmunotherapy alone had no grade 3 or 4 toxicity. With radioimmunotherapy and paclitaxel, two of three prostate cancer patients developed transient grade 4 neutropenia. Four breast cancer patients treated with radioimmunotherapy alone had grade 3 or 4 myelosuppression. With radioimmunotherapy and paclitaxel, both breast cancer patients developed grade 4 neutropenia. Three breast cancer patients required infusion of previously harvested peripheral blood stem cells because of neutropenic fever or bleeding. One patient in this trial developed human anti-mouse antibody in contrast to 12 of 17 patients in a prior trial using m170-radioimmunotherapy without cyclosporine.Conclusions:111In/90Y-m170 targets prostate and breast cancer and can be combined with paclitaxel with toxicity limited to marrow suppression at the dose levels above. The maximum tolerated dose of radioimmunotherapy and fixed-dose paclitaxel with peripheral blood stem cell support has not been reached. Cyclosporine is effective in preventing human anti-mouse antibody, suggesting the feasibility of multidose, “fractionated” therapy that could enhance clinical response.

Matching Content Categories {📚}

Health & Fitness
Science
Education

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌟 Strong Traffic: 100k - 200k visitors per month

Based on our best estimate, this website will receive around 100,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We can't tell how the site generates income.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Doi.org might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

cancer, patients, breast, dose, prostate, radioimmunotherapy, antibody, therapy, denardo, paclitaxel, radiation, tumor, imaging, clinical, toxicity, monoclonal, patient, mcim, study, studies, bone, treatment, liver, dosimetry, linker, received, trial, clin, res, hama, metastatic, doses, days, table, cyclosporine, human, tumors, tissue, antibodies, normal, oncol, treated, grade, developed, cell, disease, imaged, stem, marrow, administration,

Topics {✒️}

dota-glycyl-glycyl-glycyl-phe-m170 recent articles latest yttrium-90/indium-111-dota-peptide-chimeric l6 yttrium-90-dota-peptide-chimeric l6 radioimmunoconjugate 111in/90y-m170 targets prostate iodine-131-labeled anti-cd20 antibody cancer prevention view cancer research transformed low-grade b-cell 111in/90y-dota-peptide-m170 patient receive 90y-dota-peptide-m170 open menu tetrapeptide-linked radiometal-labeled radiopharmaceutical human anti-mouse antibody 111in-dota-peptide-m170 targeting 90y/111in-dota-peptide-m170 provide information molecular sieving chromatography california-davis cancer center granulocyte colony-stimulating factor yttrium-90-labeled anti-tac nci molecular analysis 90y/111in-2it-bad-m170 131i-anti-cd45 antibody autologous stem-cell rescue hormone-refractory prostate cancer 111in-labeled dota-peptide radiolabeled anti-cd33 antibody aberrant carbohydrate residues peptide-linked dota derivative 90y-cyt-356 monoclonal antibody 67cu-2it-bat-lym-1 recurrent b-cell lymphoma dota-peptide-linked-m170 high-performance liquid chromatography cathepsin-degradable peptide linking 90y-dota-peptide-m170 stem cell–supported radioimmunotherapy stem cell–supported radioimmunotherapy 111in-dota-peptide-m170 111in dota-peptide-m170 article abstract materials 2it-bat-lym-1 immunoconjugates radiolabeled dota-peptide-m170 111in-dota-2it-m170 small volume nodal iodine-131-anti-b1 radioimmunotherapy dota-tetrapeptide-linked m170 chemotherapy-refractory low-grade conventional 2it-bad linker

Questions {❓}

Does paclitaxel given after 111In labeled monoclonal antibodies increase tumor cumulated activity in epithelial cancers?

Schema {🗺️}

ScholarlyArticle:
      context:https://schema.org
      id:https://aacrjournals.org/clincancerres/article/11/16/5920/185630/High-Dose-Radioimmunotherapy-Combined-with-Fixed
      name:High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse Antibody
      datePublished:2005-08-22
      isPartOf:
         id:https://aacrjournals.org/clincancerres/issue/11/16
         type:PublicationIssue
         issueNumber:16
         datePublished:2005-08-15
         isPartOf:
            id:https://aacrjournals.org/clincancerres
            type:Periodical
            name:Clinical Cancer Research
            issn:
               1557-3265
      url:https://dx.doi.org/10.1158/1078-0432.CCR-05-0211
      keywords:
         Combined modality radioimmunotherapy
         Peripheral blood stem cell support
         Fractionated radioimmunotherapy
         Prostate cancer
         Breast cancer
      inLanguage:en
      copyrightHolder:
      copyrightYear:2025
      publisher:
      author:
            name:Richman, Carol M.
            affiliation:1 University of California-Davis, Sacramento, California;
            type:Person
            name:DeNardo, Sally J.
            affiliation:1 University of California-Davis, Sacramento, California;
            type:Person
            name:O'Donnell, Robert T.
            affiliation:1 University of California-Davis, Sacramento, California;
            type:Person
            name:Yuan, Aina
            affiliation:1 University of California-Davis, Sacramento, California;
            type:Person
            name:Shen, Sui
            affiliation:2 University of Alabama, Birmingham, Alabama; and
            type:Person
            name:Goldstein, Desiree S.
            affiliation:1 University of California-Davis, Sacramento, California;
            type:Person
            name:Tuscano, Joseph M.
            affiliation:1 University of California-Davis, Sacramento, California;
            type:Person
            name:Wun, Ted
            affiliation:1 University of California-Davis, Sacramento, California;
            type:Person
            name:Chew, Helen K.
            affiliation:1 University of California-Davis, Sacramento, California;
            type:Person
            name:Lara, Primo N.
            affiliation:1 University of California-Davis, Sacramento, California;
            type:Person
            name:Kukis, David L.
            affiliation:1 University of California-Davis, Sacramento, California;
            type:Person
            name:Natarajan, Arutselvan
            affiliation:1 University of California-Davis, Sacramento, California;
            type:Person
            name:Meares, Claude F.
            affiliation:1 University of California-Davis, Sacramento, California;
            type:Person
            name:Lamborn, Kathleen R.
            affiliation:3 University of California-San Francisco, San Francisco, California
            type:Person
            name:DeNardo, Gerald L.
            affiliation:1 University of California-Davis, Sacramento, California;
            type:Person
      description:Abstract. Purpose: Although radioimmunotherapy alone is effective in lymphoma, its application to solid tumors will likely require a combined modality approach. In these phase I studies, paclitaxel was combined with radioimmunotherapy in patients with metastatic hormone-refractory prostate cancer or advanced breast cancer.Experimental Design: Patients were imaged with indium-111 (111In)-1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid-peptide-m170. One week later, yttrium-90 (90Y)-m170 was infused (12 mCi/m2 for prostate cancer and 22 mCi/m2 for breast cancer). Initial cohorts received radioimmunotherapy alone. Subsequent cohorts received radioimmunotherapy followed 48 hours later by paclitaxel (75 mg/m2). Cyclosporine was given to prevent development of human anti-mouse antibody.Results: Bone and soft tissue metastases were targeted by 111In-m170 in 15 of the 16 patients imaged. Three prostate cancer patients treated with radioimmunotherapy alone had no grade 3 or 4 toxicity. With radioimmunotherapy and paclitaxel, two of three prostate cancer patients developed transient grade 4 neutropenia. Four breast cancer patients treated with radioimmunotherapy alone had grade 3 or 4 myelosuppression. With radioimmunotherapy and paclitaxel, both breast cancer patients developed grade 4 neutropenia. Three breast cancer patients required infusion of previously harvested peripheral blood stem cells because of neutropenic fever or bleeding. One patient in this trial developed human anti-mouse antibody in contrast to 12 of 17 patients in a prior trial using m170-radioimmunotherapy without cyclosporine.Conclusions:111In/90Y-m170 targets prostate and breast cancer and can be combined with paclitaxel with toxicity limited to marrow suppression at the dose levels above. The maximum tolerated dose of radioimmunotherapy and fixed-dose paclitaxel with peripheral blood stem cell support has not been reached. Cyclosporine is effective in preventing human anti-mouse antibody, suggesting the feasibility of multidose, “fractionated” therapy that could enhance clinical response.
      pageStart:5920
      pageEnd:5927
      siteName:American Association for Cancer Research
      thumbnailURL:https://aacr.silverchair-cdn.com/aacr/content_public/journal/clincancerres/issue/11/16/2/m_cover.gif?Expires=1814574248&Signature=pRMsK1Zphtc-f6bB1w3jPEgv0ufWd3CRn3cWE-EtX7ZeeCgjeY7Cyv3~ZfXrWIVMH~o2RWs4cIhrL2HBv01j8H~3FNEyO3CN5afb2viU3tmYOoisLRSY~LSaKXfoFiJgDbHRnwftcVeqytFvynzpdiDdC8QXy~bgODLrBjYJHWJHlMIZRw4VHS8CeKFqXFeJteUaMm78jUQEU52DP9OR5tx-fLd~aM9sEBEG7MFZWTTgDVTyuXaG-LLkogGDZPJ6I8sAZtbHF03JucrZECsSc0tp8h2x1GCCGwJ0L~TuJUgHLvYmXOs4HVWVvcBF6uliznBNZAYOgGqWr1FUiZlCDg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA
      headline:High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse Antibody
      image:https://aacr.silverchair-cdn.com/aacr/content_public/journal/clincancerres/issue/11/16/2/m_cover.gif?Expires=1814574248&Signature=pRMsK1Zphtc-f6bB1w3jPEgv0ufWd3CRn3cWE-EtX7ZeeCgjeY7Cyv3~ZfXrWIVMH~o2RWs4cIhrL2HBv01j8H~3FNEyO3CN5afb2viU3tmYOoisLRSY~LSaKXfoFiJgDbHRnwftcVeqytFvynzpdiDdC8QXy~bgODLrBjYJHWJHlMIZRw4VHS8CeKFqXFeJteUaMm78jUQEU52DP9OR5tx-fLd~aM9sEBEG7MFZWTTgDVTyuXaG-LLkogGDZPJ6I8sAZtbHF03JucrZECsSc0tp8h2x1GCCGwJ0L~TuJUgHLvYmXOs4HVWVvcBF6uliznBNZAYOgGqWr1FUiZlCDg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA
      image:alt:Issue Cover
PublicationIssue:
      id:https://aacrjournals.org/clincancerres/issue/11/16
      issueNumber:16
      datePublished:2005-08-15
      isPartOf:
         id:https://aacrjournals.org/clincancerres
         type:Periodical
         name:Clinical Cancer Research
         issn:
            1557-3265
Periodical:
      id:https://aacrjournals.org/clincancerres
      name:Clinical Cancer Research
      issn:
         1557-3265
Person:
      name:Richman, Carol M.
      affiliation:1 University of California-Davis, Sacramento, California;
      name:DeNardo, Sally J.
      affiliation:1 University of California-Davis, Sacramento, California;
      name:O'Donnell, Robert T.
      affiliation:1 University of California-Davis, Sacramento, California;
      name:Yuan, Aina
      affiliation:1 University of California-Davis, Sacramento, California;
      name:Shen, Sui
      affiliation:2 University of Alabama, Birmingham, Alabama; and
      name:Goldstein, Desiree S.
      affiliation:1 University of California-Davis, Sacramento, California;
      name:Tuscano, Joseph M.
      affiliation:1 University of California-Davis, Sacramento, California;
      name:Wun, Ted
      affiliation:1 University of California-Davis, Sacramento, California;
      name:Chew, Helen K.
      affiliation:1 University of California-Davis, Sacramento, California;
      name:Lara, Primo N.
      affiliation:1 University of California-Davis, Sacramento, California;
      name:Kukis, David L.
      affiliation:1 University of California-Davis, Sacramento, California;
      name:Natarajan, Arutselvan
      affiliation:1 University of California-Davis, Sacramento, California;
      name:Meares, Claude F.
      affiliation:1 University of California-Davis, Sacramento, California;
      name:Lamborn, Kathleen R.
      affiliation:3 University of California-San Francisco, San Francisco, California
      name:DeNardo, Gerald L.
      affiliation:1 University of California-Davis, Sacramento, California;

Social Networks {👍}(4)

External Links {🔗}(140)

Analytics and Tracking {📊}

Google Analytics
Google Analytics 4
Google Tag Manager
Google Universal Analytics

Libraries {📚}

jQuery
Sharethis
Umbrella.js
Video.js

Emails and Hosting {✉️}

Mail Servers:

mx.zoho.eu
mx2.zoho.eu
mx3.zoho.eu

Name Servers:

josh.ns.cloudflare.com
zita.ns.cloudflare.com

CDN Services {📦}

Com/aacr/content_public/journal/clincancerres/11/16/10
Com/aacr/content_public/journal/clincancerres/issue/11/16/2/m_cover
Com/aacr/scm
Com/data/SiteBuilderAssets/Live/CSS/clincancerres/v-638755108099649283/site
Com/data/SiteBuilderAssets/Live/Images/clincancerres/CCR-title-973029469
Com/data/SiteBuilderAssetsOriginals/Live/CSS/umbrella/v-637618851688422932/global
Com/data/SiteBuilderAssetsOriginals/Live/Images/umbrella/apple-touch-icon
Com/data/SiteBuilderAssetsOriginals/Live/Images/umbrella/favicon
Com/data/SiteBuilderAssetsOriginals/Live/Images/umbrella/favicon-16x16
Com/data/SiteBuilderAssetsOriginals/Live/Images/umbrella/favicon-32x32
Com/data/SiteBuilderAssetsOriginals/Live/images/umbrella/footer-logo
Com/data/SiteBuilderAssetsOriginals/Live/Images/umbrella/safari-pinned-tab
Com/data/SiteBuilderAssetsOriginals/Live/images/umbrella/umbrella-logo
Com/DownloadFile/DownloadImage
Com/ImageLibrary/umbrella/icons/RSS-icon-16px
Com/Themes/Client/app/css/v-638848467449541860/bg_img
Com/Themes/Client/app/css/v-638870639538673722/site
Com/Themes/Client/app/jsdist/v-638870639655202647/site
Com/Themes/Silver/app/icons/v-638848469864512582/style
Com/Themes/Silver/app/js/jquery
Com/Themes/Silver/app/vendor/v-638848469881376018/jquery-migrate-3
Crossref
Feathr
Jsdelivr

5.46s.